The majority of our resources and investment have been dedicated to rigorous research, clinical trials, regulatory compliance and hardware innovation to ensure that Nettle meets the highest standards as a safe and effective medically regulated device. This commitment includes funding three clinical trials (with many others ongoing), collaborating with top experts from leading institutions, and navigating stringent medical regulations. We prioritised these efforts so that when we introduced a brain-based, non-hormonal option for menstrual symptom management, women could trust that Nettle is certified, safe, and effective.

At Samphire, we dedicate the majority of our resources to research and development, with a strong commitment to advancing knowledge and options in women’s health. After R&D, our next largest investment is in free educational resources, accessible worldwide through our mobile app, website, social media, newsletters, in-depth guides, resources for healthcare practitioners, and community events. We believe that providing women with clear, up-to-date research on their health is the most powerful tool for empowering informed choices about their bodies and minds.

From the beginning, we committed to several key steps to achieve this: navigating medical regulations to make Nettle a prescribed treatment option, working closely with patient communities to understand their unique needs, and building strong relationships with healthcare providers who specialise in menstrual health. Additionally, we are collaborating with health systems like the NHS to gather data on the cost-effectiveness of expanding treatment options for conditions like endometriosis, PMDD, and PCOS. To further improve access, we partner with workplace wellness platforms such as Zest and Heka, broadening the availability of Nettle through employer channels.